This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.
CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $64.75, denoting a +0.12% change from the preceding trading day.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its lead drug, Trikafta/Kaftrio, and progress with other pipeline candidates.
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 13.71% and 5.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
by Zacks Equity Research
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $62.87, indicating a -0.22% shift from the previous trading day.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $61.99, denoting a +1.66% change from the preceding trading day.
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
by Zacks Equity Research
Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
by Zacks Equity Research
This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $62.63, denoting a -0.1% change from the preceding trading day.
Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why
by Zacks Equity Research
Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.
bluebird (BLUE) Stock Down on Raising Additional Capital
by Zacks Equity Research
bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy
by Zacks Equity Research
Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
by Zacks Equity Research
bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%
by Zacks Equity Research
Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
by Zacks Equity Research
Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
5 Reasons to be Bullish into 2024
by Andrew Rocco
Stock Strategist Andrew Rocco unveils 5 bullish undercurrents that will push stocks even higher into the new year.
BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies
by Zacks Equity Research
The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.
bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD
by Zacks Equity Research
bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.
After Golden Cross, CRISPR Therapeutics AG (CRSP)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy
by Zacks Equity Research
CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.
CRISPR Therapeutics and Dollar General have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
CRISPR Therapeutics and Dollar General are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
FDA approval for revolutionary Sickle Cell Disease gene-editing treatment promises a bright future
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.